2014 Fiscal Year Final Research Report
In vitro cardiotoxicity assay system using MVP technology
| Project/Area Number |
25670126
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
General pharmacology
|
|---|
| Research Institution | Tokyo Medical and Dental University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Keywords | 心毒性 / 動きベクトル |
|---|
| Outline of Final Research Achievements |
Cardiotoxicity of drugs is the main cause of drop out from the pipeline and recall from the market. Thus, the development of assay system, especially in vitro assay system in the early stage of drug development, has been strongly required from pharmaceutical companies. Here, we used multi-electrode array (MEA) system and motion vector prediction (MVP) system developed by the Sony coorporation to establish the system to simultaneously assay electrical activity and contractility in cardiomyocytes. We confirmed in human iPS-derived cardiomyocytes that drugs known to possess positive and negative inotropic effects could be reliably assayed. Recently, the cardiotoxicity of anti-cancer drugs has been strongly concerned. We successfully assayed cardiotoxicity of anticancer drugs.
|
| Free Research Field |
循環薬理
|
